AYA General Discussion, page-4

Yes and no, FDA approval might not being successful earlier this year or during 2022 when the company anticipated to receive them.

But honestly this shouldn’t be the main reason that this company is getting hammered down so badly given that the works they done aren’t receiving the American regulatory approval yet.

But I also see this stock is illiquid in nature and will have some volatility happening if one or few shareholders decided to buy in or sell out.

To me the product they are offering is like the Xero in the Coronary Heart Disease, very little capital investment needed and can be commercialised across the world quite easily and receive royalties per patient.